Progress in Neoadjuvant Immunotherapies for Resectable Non-small Cell Lung Cancer.
10.3779/j.issn.1009-3419.2020.103.07
- Author:
Shuaibo WANG
1
;
Yousheng MAO
1
Author Information
1. Department of Thoracic Surgery, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.
- Publication Type:Journal Article
- Keywords:
Immunotherapy;
Lung neoplasms;
Neoadjuvent therapy
- From:
Chinese Journal of Lung Cancer
2020;23(5):371-380
- CountryChina
- Language:Chinese
-
Abstract:
Resectable non-small cell lung cancer (NSCLC) is currently considered as a potentially curable disease. Surgery is still the main treatment mode for resectable NSCLC, but quite a few patients will have local recurrence and distant metastasis after surgery. Therefore, preoperative and postoperative adjuvant therapy may be necessary in order to improve the long term outcome. Immunocheckpoint inhibitor has been demonstrated clinically to be effective andapproved as first- or second-line treatment agent in metastatic NSCLC or partially locally advanced NSCLC. The remarkable efficacy of immunotherapy for advanced lung cancer has attracted more and more attention from the researchers to the role of immunotherapy as neoadjuvent therapy in resectable non-small cell lung cancer. This article systematically reviewed the clinical trials of neoadjuvant immunotherapy for resectable NSCLC before surgery.
